Shots:

• The Brazilian Health Regulatory Agency- ANVISA (Agencia Nacional de Vigilancia Sanitaria) has approved Herzuma (trastuzumab) in 150mg & 440mg for early-stage breast cancer- metastatic breast cancer and metastatic gastric cancer on May 20- 2019
• Celltrion is also expecting ANVISA’s approval for Truxima- a biosimilar of Rituximab which helps in securing a leading market position in the Central-South American biosimilar market
• Herzuma (trastuzumab-pkrb) is a biosimilar of Herceptin and has received FDA’s approval in Dec’18- also approved in EU (marketed by Mundipharma)- in Japan (marketed by Daiichi Sankyo) and in Australia

Ref: Celltrion | Image: Celltrion